TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Palliative Care for Elderly Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. cancer diagnosis (receiving cancer therapy or cancer control care)~2. receiving outpatient palliative care~3. age 55 years or older~4. able to speak and read English~5. physically able to complete the study (Palliative Performance Scale \[PPS\]\>50, suggesting a mean in life expectancy of 53 days at the time of enrollment since each patient is expected to participate in the study for 28-42 days maximum \[4-6 weeks\]).~Exclusion Criteria:~1. legally blind~2. cognitively unable to complete study measures (Mini Mental Status Exam \[MMSE\] does not correctly spell the word world backwards)~3. history of psychosis (medical record review)~4. Patient Dignity Inventory score that indicates their distress level falls outside the remaining quota for a given step (quota is 50% of sample/site/step with low distress ≤ 2 problems rated \>2 \& 50% with high distress ≥ 3 problems rated \>2)~5. Spiritual distress score that indicates their distress level falls outside the remaining quota for a given step (quota is 50% of sample/site/step with low distress ≤ 2 problems rated \>2 \& 50% with high distress ≥ 3 problems rated \>2)~6. are participating in another psychosocial intervention study that is focused on concepts similar to the proposed study.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- usual outpatient palliative care (Type: ACTIVE_COMPARATOR): During the usual care steps, patients will receive usual outpatient palliative care
- Dignity Therapy - Nurse Led (Type: EXPERIMENTAL): During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
- Dignity Therapy - Chaplain Led (Type: EXPERIMENTAL): During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 2 diabetes mellitus~* Treated with both metformin and a sulfonylurea at defined doses for at least 3 months prior to screening~* BMI= 27-45 kg/m2~* HbA1c value between 7.5% and 11%~Exclusion Criteria:~* Treated with oral anti-diabetic medications other than metformin and sulfonylurea within 3 months of screening~* Patients treated previously with AC2993~* Patients presently treated with insulin

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AC2993 5 mcg (0.02 mL) (Type: EXPERIMENTAL): Placebo, then AC2993 5 mcg, then AC2993 5 mcg
- AC2993 10mcg (0.04 mL) (Type: EXPERIMENTAL): Placebo, then AC2993 5 mcg, then AC2993 10 mcg
- Placebo 0.02 mL (Type: PLACEBO_COMPARATOR): Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
- Placebo 0.04 mL (Type: PLACEBO_COMPARATOR): Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* We will identify prospectively all subjects who undergo coronary stenting using the following codes for bare metal or drug eluting stents: ICD-9 procedure codes (36.06) or (36.07), MS-DRG codes 247-249 or CPT codes 92980, 92981, C1984 G0290, G0291~* We will select subjects identified as Black or Hispanics by a validated algorithm that uses the Medicare race code, geocoding techniques and the Spanish Surname list.~Exclusion Criteria:~1. Lack of medical files to document stent placement.~2. Not receiving informed consent.~3. Subjects with contraindications for antiplatelet therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Motivational interviewing (MINT) (Type: EXPERIMENTAL): The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
- Mailed DVD (Type: ACTIVE_COMPARATOR): A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telotristat Etiprate for Carcinoid Syndrome Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age~* All patients of reproductive potential must agree to use an adequate method of contraception during the study and for 12 weeks after the Follow-up visit.~* Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor~* Documented history of carcinoid syndrome~* Patient is able and willing to provide written informed consent prior to participation~Exclusion Criteria:~* Presence of diarrhea attributed to any condition other than carcinoid syndrome.~* Presence of 12 or more watery bowel movements per day~* Positive stool examination for enteric pathogens, pathogenic ova or parasites, of Clostridium difficile at Screening~* Karnofsky Performance Status ≤ 60%~* Presence of any clinically significant laboratory, medical history, or physical examination findings deemed unacceptable by the Investigator~* A history of short bowel syndrome~* History of constipation within 2 years of Screening~* Life expectancy \< 12 months from Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 250 mg Telotristat Etiprate (Type: EXPERIMENTAL): Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
- 500 mg Telotristat Etiprate (Type: EXPERIMENTAL): Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
- Placebo (Type: PLACEBO_COMPARATOR): Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed~* Patients both sexes, age between 30 and 60 years~* Diagnosis of prediabetes according American Diabetes Association criteria (fasting blood glucose levels between 100-126 mg/dl; postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose between 140-199 mg/dl; or glycosylated hemoglobin between 5.7-6.4%)~* Diagnosis of prehypertension according (JNC8) Eighth Joint National Committee blood pressure between 120-139/ 80-89 mmHg.~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to ingredients of intervention~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Diabetes diagnosis~* Previous treatment for glucose or blood pressure Triglycerides ≥400 mg/dL~* Total cholesterol ≥240 mg/dL~* History of cardiovascular disease~* Worker per shift / night

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, one per day before breakfast during 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Karnofsky score ≥ 70%~3. No evidence of progressive bacterial, viral, or fungal infection~4. Creatinine clearance \> 50 mL/min/1.72m2~5. Total bilirubin, ALT and AST \< 2 x the upper limit of normal (except for diagnosed Gilbert's syndrome)~6. Alkaline phosphatase ≤ 250 IU/L~7. Left Ventricular Ejection Fraction (LVEF) \> 45%~8. Adjusted Carbon Monoxide Diffusing Capacity (DLCO) \> 60%~9. Negative HIV serology~10. Negative pregnancy test: confirmation per negative serum β-human chorionic gonadotropin (β-hCG) for women of childbearing age and potential.~Exclusion Criteria:~1. Donors are excluded in case of donor-specific HLA antibodies or positive cross-match.~2. Pregnant or nursing females or women of child bearing age or potential, who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from the first dose of conditioning regimen through day +180. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row.~3. Male subjects who refuse to practice effective barrier contraception during the entire study treatment period and through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy).~4. Inability to provide informed consent.~5. Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix E), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.~6. Known allergies to any of the components of the investigational treatment regimen.~7. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~8. Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.~9. Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HSCT Patients (Type: EXPERIMENTAL): Adult patients with hematological malignancies undergoing HLA-haploidentical HSCT from first-or second-degree family donors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participant and/or legal representative has/have voluntarily provided signed informed consent~* Participant is 12 to 65 years old at the time of screening~* Participant is male with severe hemophilia A (Factor VIII (FVIII) clotting activity \< 1%) as confirmed by central laboratory at screening after the appropriate washout period or a documented FVIII clotting activity \<1%~* Participant has been previously treated with plasma-derived FVIII concentrates or recombinant FVIII for ≥150 documented exposure days (EDs)~* Participant is currently receiving prophylaxis or on-demand therapy with FVIII~* Participant is willing and able to comply with the requirements of the protocol~Main Exclusion Criteria:~* Participant has detectable FVIII inhibitory antibodies (≥ 0.6 Bethesda Units (BU) using the Nijmegen modification of the Bethesda assay) as confirmed by central laboratory at screening~* Participant has history of FVIII inhibitory antibodies (≥ 0.4 BU using the Nijmegen modification of the Bethesda assay or ≥ 0.6 BU using the Bethesda assay) at any time prior to screening~* Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (eg, qualitative platelet defect or von Willebrand's disease).

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis (Type: EXPERIMENTAL): None
- On-demand (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 12 years of age; diagnosed with clinically confirmed C1-INH hereditary angioedema; experience ≥ 3 attacks during the 3 months before screening.~Note: For subjects taking any prophylactic HAE therapy during the 3 months before Screening, ≥ 3 HAE attacks may be documented over 3 consecutive months before commencing the prophylactic therapy.~Exclusion Criteria:~* Concomitant diagnosis of another form of angioedema such as idiopathic or acquired angioedema, recurrent angioedema associated with urticarial or hereditary angioedema type 3

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CSL312 (Type: EXPERIMENTAL): Participants received a CSL312 loading dose of 400 mg as two 200 mg SC injections in Month 1 along with CSL312 of 200 mg subcutaneous (SC) injections, once monthly from Months 2 to 6.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a CSL312 matched loading dose of placebo as two SC injections in Month 1 along with CSL312 matched placebo SC injections, once monthly from Months 2 to 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least one risk for postpartum hemorrhage and lack of hypersensitivity to oxytocin and carbetocin~Exclusion Criteria:~* Patients' refusal to cooperate, major therapeutic side effects, history of cardiac and renal disease or preeclampsia

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Oxytocin (Type: EXPERIMENTAL): A single 100 microgram IV dose of carbetocin after operation
- Carbetocin (Type: EXPERIMENTAL): A standard 30 international units (IU) IV infusion of oxytocin during two hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of adenocarcinoma of the esophagus meeting the following criteria:~  * Stage II or III disease~ * Resectable disease~ * Previously untreated disease~* No stage I (mucosal only) or stage IV (metastatic) disease~PATIENT CHARACTERISTICS:~* WBC \> 3,000/mm\^3~* Absolute neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~* Creatinine ≤ 2.0 mg/dL~* Bilirubin \< 2 times normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Must have central venous access~* No other malignancy within the past 5 years~* No concurrent medical or psychiatric problem that would preclude study treatment~* No contraindications to paclitaxel~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy to the esophagus~* No oral cryotherapy (e.g., ice chips) on day 1 of each course

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant + Adjuvant Chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* LV less than 35%, as defined by echocardiogram, left ventriculogram, CMR, or gated single photon emission computed tomography (SPECT) studies~* Coronary anatomy suitable for revascularization~Exclusion Criteria:~* Failure to provide informed consent.~* Aortic valvular heart disease clearly indicating the need for aortic valve repair or replacement.~* Cardiogenic shock (within 72 hours of randomization), as defined by the need for intraaortic balloon support or the requirement for intravenous inotropic support.~* Plan for percutaneous intervention of CAD.~* Recent acute MI judged to be an important cause of left ventricular dysfunction.~* History of more than 1 prior coronary bypass operation.~* Noncardiac illness with a life expectancy of less than 3 years.~* Noncardiac illness imposing substantial operative mortality.~* Conditions/circumstances likely to lead to poor treatment adherence (eg, history of poor compliance, alcohol or drug dependency, psychiatric illness, no fixed abode).~* Previous heart, kidney, liver, or lung transplantation.~* Current participation in another clinical trial in which a patient is taking an investigational drug or receiving an investigational medical device.~MED Therapy Eligibility Criteria~* Absence of left main CAD as defined by an intraluminal stenosis of 50% or greater.~* Absence of CCS III angina or greater (angina markedly limiting ordinary activity).~SVR Eligibility Criterion~• Dominant akinesia or dyskinesia of the anterior left ventricular wall amenable to SVR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- H01: Medication (Type: ACTIVE_COMPARATOR): Medical therapy alone to treat Coronary Artery Disease
- H01: Medication + CABG (Type: ACTIVE_COMPARATOR): Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
- H02: Medication+CABG (Type: ACTIVE_COMPARATOR): Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
- H02: Medication+CABG+SVR (Type: ACTIVE_COMPARATOR): CABG plus Medication and Surgical ventricular reconstruction (SVR)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete